The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Duration of response (DoR) following treatment with UGN-102 in patients with recurrent, low-grade, intermediate-risk, non-muscle invasive, bladder cancer: 18-month DoR data from the phase 3 ENVISION trial.
 
Sandip Prasad
Stock and Other Ownership Interests - MetasTx (Inst)
Consulting or Advisory Role - UroGen pharma
Speakers' Bureau - UroGen pharma
Research Funding - Genentech; Merck; UroGen pharma
(OPTIONAL) Uncompensated Relationships - UroGen pharma
 
Nikola Mihaylov
(OPTIONAL) Uncompensated Relationships - UroGen pharma
 
Alexandre Khuskivadze
Research Funding - UroGen pharma
 
Pencho Genov
(OPTIONAL) Uncompensated Relationships - UroGen pharma
 
Vasyl Terzi
(OPTIONAL) Uncompensated Relationships - UroGen pharma
 
Max Kates
Honoraria - American Urological Association; BCAN; Kaplan; MedStar Health; Urology Times
Consulting or Advisory Role - Aura; Flashpoint; ImmunityBio; Merck; Pfizer; Protara Therapeutics; UroGen pharma
(OPTIONAL) Uncompensated Relationships - UroGen pharma
 
William Huang
Honoraria - UroGen pharma
Consulting or Advisory Role - UroGen pharma
Speakers' Bureau - UroGen pharma
Research Funding - Histosonics; Intuitive Surgical; Merck; Photocure; UroGen pharma
 
Michael Louie
Employment - UroGen pharma
Stock and Other Ownership Interests - UroGen pharma
 
Sunil Raju
Employment - UroGen pharma
Stock and Other Ownership Interests - UroGen pharma
 
Brent Burger
Employment - UroGen pharma
Stock and Other Ownership Interests - UroGen pharma
 
Andrew Meads
Employment - UroGen pharma
Stock and Other Ownership Interests - UroGen pharma
 
Dimitar Shishkov
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb
Research Funding - PSI
(OPTIONAL) Uncompensated Relationships - UroGen pharma
 
on behalf of The ENVISION Study Group
No Relationships to Disclose